AMENDMENTS TO THE SPECIFICATION

On Page 1, lin 1 please add:

This application is a continuation application of U.S. Application 09/408,328 filed on September 29, 1999 and claims priority thereto under 35 U.S.C. § 120.

On Page 10, lines 13-14

preferred method, the strain of F. necrophorum bacteria used is obtained from a bovine and identified as strain number 021496, ATCC No. [[____]] PTA-917.

Page 15 line 14 through Page 16, line 4

releasing them in the host after vaccination. Representative examples of suitable adjuvants are aluminum salts, such as aluminum hydroxide and aluminum phosphate; polymers, such as POLYGEN™, DEAE dextran, dextran sulfate, and ~~methyacrylates~~ methacrylates; dimethylo-decylammonium bromide; poxvirus proteins, such as Baypamune®; Avirdine, Lipid A; oils, such as EMULSIGEN™, EMULSIGEN PLUS™, and SuprImm®; animal oils, such as squalane or squalene; mineral oils, such as Drakeol® and ~~Montanides~~ Montanide ®; vegetable oils, such as peanut oil; block co-polymers; triterpenoid glycosides, such as saponin, ~~QuilA~~ Quil A™, and QS21™; detergents, such as ~~Tween-80~~ TWEEN™-80 and ~~Pluronic~~ PLURONIC™; bacterial component adjuvants, such as Corynebacterium, Propionibacterium, and Mycobacterium; interleukins, monokines, and interferons; liposomes; ISCOMs; synthetic glycopeptides, such as muryamyl dipeptides and derivatives thereof, cholera toxin; or combinations of the above. More preferably, the adjuvant is

Page 17, lines 7-9

by the amount of bacteria and the antigenicity of the culture found in the vaccine. As such, any reasonable amount can be administered, with it being preferred that the dosage be between 1 ml and 5 ml. A dosage of 2 ml is even more preferred. The smaller doses are preferred